Asthma season is in full swing and AstraZeneca is raising awareness about its severe asthma treatment, Fasenra, as part of its ongoing Stepping Back Out campaign. The latest installment of the ...
Teaming with the Professional Pickleball Association (PPA) in a multiyear deal, AstraZeneca’s seven-year-old Fasenra asthma medication has launched its first-ever sports partnership. The brand began ...
AstraZeneca experienced some setbacks last year on its quest to expand its asthma drug Fasenra to treat other conditions like rhinosinusitis and eosinophilic esophagitis. However, the British pharma ...
AstraZeneca is stepping back into Fasenra promotion to show how its asthma treatment can help people with asthma step back out. The ad opens with a feed of social media posts on a tablet screen. In ...
Some people with very severe asthma symptoms have a condition called eosinophilic asthma. People with this type of asthma may need to use inhaled medicines along with a newer type of medicine that is ...
Dr. Michael Wechsler, Professor of Medicine and Director of The Asthma Institute at National Jewish Health, and International Coordinating Investigator of the MANDARA trial said: “This approval is ...
AstraZeneca is refreshing its Fasenra campaign. Almost six years into the launch, the Big Pharma has established consistent messaging across physicians and patients for the first time, tying the brand ...
No new safety signals were identified in the pediatric trial. The Food and Drug Administration (FDA) has expanded the approval of Fasenra (benralizumab) for add-on maintenance treatment of severe ...
Please provide your email address to receive an email when new articles are posted on . The approval follows positive results from the TATE trial. A new 10 mg dose will be available to accommodate ...
AstraZeneca has launched campaigns for two prescription asthma medications: AirSupra and Fasenra. Standard rescue inhaler albuterol is compared to a dinosaur -- who however cute he is, still ...
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s FASENRA (benralizumab) met the primary endpoint of the trial and demonstrated ...
On 28 September 2025, at the European Respiratory Society (ERS) congress in Amsterdam, the Netherlands, results from a post hoc analysis of the ANANKE (NCT04272463) study were presented. The study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results